Investors & News / Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update Read more about Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update 2023 Annual Report (pdf) Read more about 2023 Annual Report (pdf) Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024 Read more about Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024 Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March Read more about Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update Read more about Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update S. Gail Eckhardt Member of the Research & Development CommitteeMember of the Compensation Committee S. Gail Eckhardt Mary C. Beckerle Member of the Nominating and Corporate Governance CommitteeMember of the Research & Development Committee Mary C. Beckerle Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February Read more about Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024 Read more about Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024 Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024 Read more about Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024 Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last » Subscribe to Receive Email Alerts Sign up to receive email alerts whenever Exelixis, Inc. posts new information to the site. Just enter your email address and click Submit. Required fields denoted by an asterisk (). Alert type Exelixis SEC Alert Exelixis End-of-Day SEC Alert Exelixis Calendar Alert Exelixis News Alert Exelixis Report Alert Email Leave this field blank Shareholder Tools Information Request Print Page RSS
Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update Read more about Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024 Read more about Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March Read more about Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update Read more about Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update
S. Gail Eckhardt Member of the Research & Development CommitteeMember of the Compensation Committee S. Gail Eckhardt
Mary C. Beckerle Member of the Nominating and Corporate Governance CommitteeMember of the Research & Development Committee Mary C. Beckerle
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February Read more about Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024 Read more about Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024 Read more about Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024